-
Product Insights
Transcription Factor EB – Drugs In Development, 2023
Global Markets Direct’s Transcription Factor EB provides in depth analysis on Transcription Factor EB targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Transcription Factor EB targeted therapeutics...
-
Product Insights
NewNet Present Value Model: Edesa Biotech Inc’s EB-05
Empower your strategies with our Net Present Value Model: Edesa Biotech Inc's EB-05 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Edesa Biotech Inc’s EB-01
Empower your strategies with our Net Present Value Model: Edesa Biotech Inc's EB-01 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Edesa Biotech Inc’s EB-02
Empower your strategies with our Net Present Value Model: Edesa Biotech Inc's EB-02 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Centanafadine SR in Major Depressive Disorder
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Centanafadine SR in Major Depressive Disorder report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Centanafadine SR in Major Depressive Disorder Drug Details: Centanafadine SR...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – EB-613 in Osteoporosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EB-613 in Osteoporosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.EB-613 in Osteoporosis Drug Details:EB-613 (Teriparatide) is under development for the treatment of post...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EB-101 in Keratoconjunctivitis Sicca (Dry Eye)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EB-101 in Keratoconjunctivitis Sicca (Dry Eye) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.EB-101 in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: EB-101 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EBS-Lassa in Lassa Fever (Lassa Hemorrhagic Fever)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EBS-Lassa in Lassa Fever (Lassa Hemorrhagic Fever) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.EBS-Lassa in Lassa Fever (Lassa Hemorrhagic Fever)Drug Details:Vaccine is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – EB-203 in Wet (Neovascular / Exudative) Macular Degeneration
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EB-203 in Wet (Neovascular / Exudative) Macular Degeneration report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EB-203 in Wet (Neovascular / Exudative) Macular...